Thrombolytic therapy for acute ischemic stroke: risks vs benefits.
Lindbloom
Erik J
EJ
Department of Family and Community Medicine, University of Missouri-Columbia, Columbia, MO, USA. lindbloome@health.missouri.edu
D002545:Brain Ischemia / Q000150:complications; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000209:etiology; D015201:Meta-Analysis as Topic; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator